Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 6,760.00
-40.00 (-0.59%)
Last updated: Apr 29, 2026, 2:19 PM KST
Kyongbo Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 264,104 | 238,556 | 216,357 | 196,265 | 170,660 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | -0 | Upgrade
|
| Revenue | 264,104 | 238,556 | 216,357 | 196,265 | 170,660 | Upgrade
|
| Revenue Growth (YoY) | 10.71% | 10.26% | 10.24% | 15.00% | -20.73% | Upgrade
|
| Cost of Revenue | 161,800 | 149,282 | 153,781 | 152,397 | 135,929 | Upgrade
|
| Gross Profit | 102,304 | 89,274 | 62,576 | 43,867 | 34,731 | Upgrade
|
| Selling, General & Admin | 77,403 | 63,411 | 50,588 | 37,580 | 34,398 | Upgrade
|
| Research & Development | 18,158 | 12,166 | 3,654 | 3,077 | 5,053 | Upgrade
|
| Amortization of Goodwill & Intangibles | 853.05 | 759.97 | 565.86 | 467.2 | 553.1 | Upgrade
|
| Other Operating Expenses | 837.05 | 640.38 | 608.67 | 586.91 | 594.64 | Upgrade
|
| Operating Expenses | 98,786 | 78,821 | 57,032 | 42,475 | 41,356 | Upgrade
|
| Operating Income | 3,519 | 10,454 | 5,545 | 1,393 | -6,625 | Upgrade
|
| Interest Expense | -4,290 | -4,290 | -3,401 | -1,671 | -1,176 | Upgrade
|
| Interest & Investment Income | 41.3 | 70.32 | 143.42 | 14.44 | 25.35 | Upgrade
|
| Earnings From Equity Investments | 4,151 | -1,376 | -376.33 | -463.72 | -85.58 | Upgrade
|
| Currency Exchange Gain (Loss) | 240.03 | -229.62 | 399.22 | -752.16 | 1,402 | Upgrade
|
| Other Non Operating Income (Expenses) | -3,074 | 410.06 | 57.91 | 877.72 | 302.77 | Upgrade
|
| EBT Excluding Unusual Items | 586.59 | 5,039 | 2,368 | -602.15 | -6,156 | Upgrade
|
| Gain (Loss) on Sale of Investments | 12.02 | -130 | -228.13 | -134.66 | -3,836 | Upgrade
|
| Gain (Loss) on Sale of Assets | -149.12 | -6.29 | -11.09 | 121.98 | 58.68 | Upgrade
|
| Asset Writedown | - | - | 43.11 | - | - | Upgrade
|
| Pretax Income | 449.49 | 4,903 | 2,172 | -614.83 | -9,933 | Upgrade
|
| Income Tax Expense | 267.2 | 263.71 | -802.48 | -1,225 | -2,438 | Upgrade
|
| Net Income | 182.29 | 4,639 | 2,974 | 610.59 | -7,495 | Upgrade
|
| Net Income to Common | 182.29 | 4,639 | 2,974 | 610.59 | -7,495 | Upgrade
|
| Net Income Growth | -96.07% | 55.97% | 387.13% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 23 | 24 | 24 | 23 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 24 | 24 | 23 | 24 | Upgrade
|
| Shares Change (YoY) | -4.71% | 0.03% | 1.80% | -1.62% | -0.25% | Upgrade
|
| EPS (Basic) | 8.00 | 194.00 | 124.42 | 26.00 | -314.00 | Upgrade
|
| EPS (Diluted) | 8.00 | 194.00 | 124.42 | 26.00 | -314.00 | Upgrade
|
| EPS Growth | -95.88% | 55.93% | 378.52% | - | - | Upgrade
|
| Free Cash Flow | -34,083 | -12,547 | -4,849 | -2,747 | 461.73 | Upgrade
|
| Free Cash Flow Per Share | -1495.72 | -524.69 | -202.82 | -116.97 | 19.34 | Upgrade
|
| Gross Margin | 38.74% | 37.42% | 28.92% | 22.35% | 20.35% | Upgrade
|
| Operating Margin | 1.33% | 4.38% | 2.56% | 0.71% | -3.88% | Upgrade
|
| Profit Margin | 0.07% | 1.94% | 1.38% | 0.31% | -4.39% | Upgrade
|
| Free Cash Flow Margin | -12.90% | -5.26% | -2.24% | -1.40% | 0.27% | Upgrade
|
| EBITDA | 16,723 | 22,862 | 17,244 | 13,328 | 6,132 | Upgrade
|
| EBITDA Margin | 6.33% | 9.58% | 7.97% | 6.79% | 3.59% | Upgrade
|
| D&A For EBITDA | 13,204 | 12,408 | 11,699 | 11,936 | 12,757 | Upgrade
|
| EBIT | 3,519 | 10,454 | 5,545 | 1,393 | -6,625 | Upgrade
|
| EBIT Margin | 1.33% | 4.38% | 2.56% | 0.71% | -3.88% | Upgrade
|
| Effective Tax Rate | 59.44% | 5.38% | - | - | - | Upgrade
|
| Advertising Expenses | 5,891 | 3,905 | 3,683 | 1,755 | 4,234 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.